BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Rating of “Hold” from Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have been assigned an average recommendation of “Hold” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $31.3750.

Several equities research analysts have commented on BLFS shares. TD Cowen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating and lowered their target price for the company from $33.00 to $31.00 in a research note on Wednesday, July 22nd. William Blair set a $31.00 price objective on BioLife Solutions in a report on Thursday, July 23rd. Benchmark downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Monday, August 10th. Stephens reaffirmed an “equal weight” rating and issued a $31.00 target price (down from $32.00) on shares of BioLife Solutions in a research report on Monday, July 27th. Finally, Zacks Research upgraded BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 28th.

BioLife Solutions Stock Up 0.4%

BLFS stock opened at $37.10 on Friday. BioLife Solutions has a twelve month low of $17.86 and a twelve month high of $38.10. The company has a market cap of $1.81 billion, a P/E ratio of 31.98 and a beta of 1.93. The business has a fifty day moving average of $30.34 and a 200-day moving average of $24.86.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.88. BioLife Solutions had a return on equity of 2.70% and a net margin of 53.29%.The business had revenue of $28.47 million for the quarter, compared to analysts’ expectations of $27.80 million. As a group, equities research analysts anticipate that BioLife Solutions will post 0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at approximately $30,000. Kemnay Advisory Services Inc. acquired a new position in BioLife Solutions during the fourth quarter worth $35,000. Quarry LP increased its holdings in BioLife Solutions by 50.9% during the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 713 shares during the last quarter. Hantz Financial Services Inc. raised its position in BioLife Solutions by 42.4% during the fourth quarter. Hantz Financial Services Inc. now owns 2,673 shares of the medical equipment provider’s stock worth $65,000 after acquiring an additional 796 shares in the last quarter. Finally, State of Wyoming bought a new stake in BioLife Solutions during the first quarter worth $52,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.